文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血清生物标志物与接受ECMO治疗的心脏骤停患者结局的相关性

Association of serum biomarkers with outcomes of cardiac arrest patients undergoing ECMO.
PubMed 文献 · Am J Emerg Med · 2018-03-10
一句话结论系统评价与Meta分析显示,高血清乳酸水平与接受ECMO治疗的心脏骤停患者较差的生存率和神经功能结局相关。

该研究为系统评价与Meta分析,检索截至2018年1月的英文数据库(PubMed、ISI web of science、Embase)和中文数据库(万方、CNKI),纳入17篇文献共903例接受ECMO治疗的心脏骤停患者。汇总分析显示,高乳酸水平与较差的生存率(N=13,OR=1.335,95%CI=1.167-1.527,P<0.001)和较差的神经功能结局(N=2,HR=1.058,95%CI=1.020-1.098,P=0.002)显著相关;高肌酐与较差的生存率也存在轻微显著关联(N=7,OR=1.010,95%CI=1.002-1.018,P=0.015)。作者认为高血清乳酸水平与接受ECMO治疗的心脏骤停患者较差的生存率和神经功能结局相关。

要点

  • 高乳酸水平与接受ECMO治疗的心脏骤停患者较差的生存率相关(N=13,OR=1.335,95%CI=1.167-1.527,P<0.001)。
  • 高乳酸水平与接受ECMO治疗的心脏骤停患者较差的神经功能结局相关(N=2,HR=1.058,95%CI=1.020-1.098,P=0.002)。
  • 高肌酐与接受ECMO治疗的心脏骤停患者较差的生存率存在轻微显著关联(N=7,OR=1.010,95%CI=1.002-1.018,P=0.015)。
  • 该Meta分析纳入17篇文献共903例接受ECMO治疗的心脏骤停患者。
  • 作者认为需进一步开展设计良好、样本量更大的研究来确认上述结果。

适用人群与场景

  • 接受体外膜肺氧合(ECMO)治疗的心脏骤停患者。

研究设计与关键结果

  • 研究类型为系统评价与Meta分析,纳入17篇文献共903例接受ECMO治疗的心脏骤停患者。
  • 高乳酸水平与较差的生存率相关(N=13,OR=1.335,95%CI=1.167-1.527,P<0.001)。
  • 高乳酸水平与较差的神经功能结局相关(N=2,HR=1.058,95%CI=1.020-1.098,P=0.002)。
  • 高肌酐与较差的生存率存在轻微显著关联(N=7,OR=1.010,95%CI=1.002-1.018,P=0.015)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析。
  • 局限:作者指出需进一步开展设计良好、样本量更大的研究来确认结果。

对床旁实践的改变

  • 作者认为高血清乳酸水平与接受ECMO治疗的心脏骤停患者较差的生存率和神经功能结局相关。
  • 作者认为需进一步开展设计良好、样本量更大的研究来确认上述结果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recently, a series of studies have been conducted to investigate the association of the common biochemical biomarkers, such as serum lactate and creatinine, with clinical outcomes in cardiac arrest patients treated with extracorporeal membrane oxygenation (ECMO), however, the results were not consistent and the sample size of primary studies is limited. In the present study, we performed a systematic review and meta-analysis to summarize the associations.

METHODS: Relevant studies in English databases (PubMed, ISI web of science, and Embase) and Chinese databases (Wanfang and CNKI) up to January 2018 were systematically searched. Crude ORs or HRs from the included studies were extracted and pooled to summarize the associations of lactate and creatinine with clinical outcomes including survival and neurological outcomes in ECMO treated cardiac arrest patients.

RESULTS: 17 papers containing 903 cases were included in the present meta-analysis study. After pooling all the eligible studies, we identified the significant associations of high lactate level with poor survival (N=13, OR=1.335, 95%CI=1.167-1.527, P<0.001) and poor neurological outcome (N=2, HR=1.058, 95%CI=1.020-1.098, P=0.002) in CA patients treated with ECMO and a slight significant association of high creatinine with poor survival was also found (N=7, OR=1.010, 95%CI=1.002-1.018, P=0.015).

CONCLUSIONS: High serum lactate level was associated with poor survival and poor neurological outcome in CA patients treated with ECMO. Further well-designed studies with larger sample size should be conducted to confirm the results.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Zhang Y, Li CS, Yuan XL, et al. Association of serum biomarkers with outcomes of cardiac arrest patients undergoing ECMO. Am J Emerg Med. 2018. PMID: 29559353. doi:10.1016/j.ajem.2018.03.015

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。